Symbols / FNCH $9.20 +0.00% Finch Therapeutics Group Inc

Healthcare • Biotechnology • United States • PNK
FNCH Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Matthew P. Blischak J.D.
Exch · Country PNK · United States
Market Cap 14.77M
Enterprise Value 25.78M
Income -14.17M
Sales —
FCF (ttm) -15.96M
Book/sh 8.86
Cash/sh 9.99
Employees 1
Insider 10d —
IPO Mar 19, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.45
PEG —
P/S inf
P/B 1.04
P/C —
EV/EBITDA -1.32
EV/Sales —
Quick Ratio 3.59
Current Ratio 3.87
Debt/Eq 203.88
LT Debt/Eq —
EPS (ttm) -8.80
EPS next Y -20.59
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-08-10
Earnings (prior) 2023-08-10
ROA -21.89%
ROE -67.28%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.61M
Shs Float 1.56M
Insider Own 3.40%
Instit Own 0.00%
Short Float 2.76%
Short Ratio 0.19
Short Interest 19.20K
52W High 16.10
vs 52W High -42.86%
52W Low 2.00
vs 52W Low 360.00%
Beta 1.17
Impl. Vol. —
Rel Volume 19.66
Avg Volume 3.65K
Volume 71.79K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $9.20
Price $9.20
Change 0.00%
About

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$9.20
Latest analyst target
3. DCF / Fair value
$-178.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.20
Low
—
High
—
Mean
—
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-06-07 SMISEK JEFFERY A Director — 767 $0.00 $0
2024-05-20 SMISEK JEFFERY A Director — 3,750 $0.00 $0
2024-03-28 SMISEK JEFFERY A Director — 8,242 $2.57 $21,246
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.11
-87.57%
0.86
-95.35%
18.53
Operating Revenue
0.11
-87.57%
0.86
-95.35%
18.53
Operating Expense
34.11
-61.70%
89.06
+13.42%
78.52
Research And Development
7.20
-86.38%
52.86
-7.71%
57.28
Selling General And Administration
26.91
-25.65%
36.19
+70.41%
21.24
General And Administrative Expense
26.91
-25.65%
36.19
+70.41%
21.24
Salaries And Wages
3.66
-69.45%
11.97
+2.05%
11.73
Other Gand A
23.25
-4.00%
24.22
+154.74%
9.51
Total Expenses
34.11
-61.70%
89.06
+13.42%
78.52
Operating Income
-34.00
+61.45%
-88.19
-47.03%
-59.98
Total Operating Income As Reported
-83.86
+27.45%
-115.59
-92.70%
-59.98
EBITDA
-32.48
+60.72%
-82.69
-43.34%
-57.68
Normalized EBITDA
17.35
+131.39%
-55.28
+7.15%
-59.54
Reconciled Depreciation
1.52
-72.40%
5.51
+139.33%
2.30
EBIT
-34.00
+61.45%
-88.19
-47.03%
-59.98
Total Unusual Items
-49.84
-81.84%
-27.41
-1577.41%
1.85
Total Unusual Items Excluding Goodwill
-49.84
-81.84%
-27.41
-1577.41%
1.85
Special Income Charges
-49.84
-81.84%
-27.41
-1577.41%
1.85
Other Special Charges
0.61
—
-1.83
Impairment Of Capital Assets
46.04
+84.29%
24.98
0.00
Restructuring And Mergern Acquisition
3.82
+58.03%
2.42
0.00
Net Income
-74.75
+34.80%
-114.65
-97.12%
-58.16
Pretax Income
-78.22
+31.78%
-114.65
-97.12%
-58.16
Net Non Operating Interest Income Expense
1.57
+523.02%
0.25
+1045.45%
0.02
Net Interest Income
1.57
+523.02%
0.25
+1045.45%
0.02
Interest Income Non Operating
1.57
+523.02%
0.25
+1045.45%
0.02
Interest Income
1.57
+523.02%
0.25
+1045.45%
0.02
Other Income Expense
-45.78
-71.45%
-26.70
-1581.09%
1.80
Other Non Operating Income Expenses
4.05
+477.35%
0.70
+1450.00%
-0.05
Tax Provision
-3.46
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
-2.21
0.00
0.00
Net Income Including Noncontrolling Interests
-74.75
+34.80%
-114.65
-97.12%
-58.16
Net Income From Continuing Operation Net Minority Interest
-74.75
+34.80%
-114.65
-97.12%
-58.16
Net Income From Continuing And Discontinued Operation
-74.75
+34.80%
-114.65
-97.12%
-58.16
Net Income Continuous Operations
-74.75
+34.80%
-114.65
-97.12%
-58.16
Normalized Income
-27.13
+68.90%
-87.24
-45.36%
-60.02
Net Income Common Stockholders
-74.75
+34.80%
-114.65
-97.12%
-58.16
Diluted EPS
-46.59
+35.29%
-72.00
-62.16%
-44.40
Basic EPS
-46.59
+35.29%
-72.00
-62.16%
-44.40
Basic Average Shares
1.60
+0.93%
1.59
+21.66%
1.31
Diluted Average Shares
1.60
+0.93%
1.59
+21.66%
1.31
Diluted NI Availto Com Stockholders
-74.75
+34.80%
-114.65
-97.12%
-58.16
Gain On Sale Of PPE
0.64
+9200.00%
-0.01
-125.00%
0.03
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
55.37
-66.02%
162.94
-27.70%
225.37
Current Assets
25.85
-65.33%
74.55
-47.70%
142.55
Cash Cash Equivalents And Short Term Investments
25.12
-64.63%
71.04
-46.78%
133.48
Cash And Cash Equivalents
25.12
-64.63%
71.04
-46.78%
133.48
Receivables
0.00
-100.00%
0.14
-70.85%
0.49
Accounts Receivable
0.00
-100.00%
0.14
-70.85%
0.49
Prepaid Assets
—
—
8.58
Other Current Assets
0.72
-78.54%
3.37
-60.72%
8.58
Total Non Current Assets
29.53
-66.60%
88.39
+6.73%
82.82
Net PPE
27.18
-44.18%
48.69
+97.21%
24.69
Gross PPE
27.45
-52.65%
57.97
+100.50%
28.91
Accumulated Depreciation
-0.28
+97.04%
-9.29
-119.73%
-4.23
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
0.87
-87.20%
6.79
+17.28%
5.79
Construction In Progress
0.00
-100.00%
0.32
-3.95%
0.33
Other Properties
26.58
-27.95%
36.90
+314.44%
8.90
Leases
0.00
-100.00%
13.97
+0.56%
13.89
Goodwill And Other Intangible Assets
0.00
-100.00%
32.90
-35.44%
50.96
Goodwill
—
0.00
-100.00%
18.06
Other Intangible Assets
—
32.90
+0.00%
32.90
Non Current Deferred Assets
—
—
0.00
Other Non Current Assets
2.35
-65.47%
6.80
-5.20%
7.17
Total Liabilities Net Minority Interest
32.49
-51.68%
67.23
+190.46%
23.14
Current Liabilities
4.08
-72.20%
14.69
-0.68%
14.79
Payables And Accrued Expenses
2.24
-78.86%
10.58
+14.22%
9.26
Payables
0.56
-71.55%
1.97
-47.42%
3.74
Accounts Payable
0.14
-87.15%
1.10
-70.64%
3.74
Current Accrued Expenses
1.68
-80.53%
8.61
+55.92%
5.52
Pensionand Other Post Retirement Benefit Plans Current
0.12
-81.62%
0.68
-84.55%
4.40
Total Tax Payable
0.42
-51.84%
0.87
—
Current Debt And Capital Lease Obligation
1.72
-49.78%
3.43
+204.17%
1.13
Current Capital Lease Obligation
1.72
-49.78%
3.43
+204.17%
1.13
Current Deferred Liabilities
—
—
0.00
Current Deferred Revenue
—
—
0.00
Total Non Current Liabilities Net Minority Interest
28.40
-45.94%
52.54
+528.83%
8.36
Long Term Debt And Capital Lease Obligation
28.40
-41.93%
48.91
+900.78%
4.89
Long Term Debt
—
14.65
—
Long Term Capital Lease Obligation
28.40
-17.08%
34.26
+600.94%
4.89
Non Current Deferred Liabilities
0.00
-100.00%
3.46
+0.00%
3.46
Non Current Deferred Revenue
—
—
0.00
Non Current Deferred Taxes Liabilities
0.00
-100.00%
3.46
+0.00%
3.46
Other Non Current Liabilities
—
0.17
+2328.57%
0.01
Preferred Securities Outside Stock Equity
0.00
0.00
0.00
Stockholders Equity
22.89
-76.09%
95.71
-52.67%
202.22
Common Stock Equity
22.89
-76.09%
95.71
-52.67%
202.22
Capital Stock
0.00
+0.00%
0.00
-95.74%
0.05
Common Stock
0.00
+0.00%
0.00
-95.74%
0.05
Share Issued
1.61
+0.25%
1.60
+1.14%
1.58
Ordinary Shares Number
1.61
+0.25%
1.60
+1.14%
1.58
Additional Paid In Capital
373.28
+0.52%
371.35
+2.25%
363.17
Retained Earnings
-350.39
-27.12%
-275.64
-71.21%
-161.00
Total Equity Gross Minority Interest
22.89
-76.09%
95.71
-52.67%
202.22
Total Capitalization
22.89
-79.26%
110.36
-45.42%
202.22
Working Capital
21.76
-63.64%
59.86
-53.15%
127.76
Invested Capital
22.89
-79.26%
110.36
-45.42%
202.22
Total Debt
30.13
-42.44%
52.34
+770.14%
6.01
Capital Lease Obligations
30.13
-20.06%
37.69
+526.53%
6.01
Net Tangible Assets
22.89
-63.56%
62.81
-58.48%
151.27
Tangible Book Value
22.89
-63.56%
62.81
-58.48%
151.27
Duefrom Related Parties Current
—
—
0.00
Dueto Related Parties Current
—
—
0.00
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-31.50
+57.91%
-74.85
-11.50%
-67.13
Cash Flow From Continuing Operating Activities
-31.50
+57.91%
-74.85
-11.50%
-67.13
Net Income From Continuing Operations
-74.75
+34.80%
-114.65
-97.12%
-58.16
Depreciation Amortization Depletion
1.52
-72.40%
5.51
+139.33%
2.30
Depreciation And Amortization
1.52
-72.40%
5.51
+139.33%
2.30
Other Non Cash Items
1.91
-36.68%
3.02
+230.56%
0.91
Stock Based Compensation
1.93
-75.41%
7.84
+88.51%
4.16
Asset Impairment Charge
46.04
+84.29%
24.98
0.00
Deferred Tax
-3.46
0.00
—
Deferred Income Tax
-3.46
0.00
—
Operating Gains Losses
0.73
+10314.29%
0.01
+100.38%
-1.84
Gain Loss On Sale Of PPE
-0.64
-9200.00%
0.01
+125.00%
-0.03
Change In Working Capital
-5.42
-246.55%
-1.56
+89.22%
-14.51
Change In Receivables
0.14
-59.14%
0.35
-41.76%
0.60
Changes In Account Receivables
0.14
-59.14%
0.35
-35.19%
0.54
Change In Prepaid Assets
2.12
+183.87%
-2.53
+21.39%
-3.22
Change In Payables And Accrued Expense
-8.79
-334.47%
-2.02
-127.21%
7.43
Change In Accrued Expense
-7.83
-3403.38%
0.24
-95.64%
5.43
Change In Payable
-0.96
+57.68%
-2.26
-213.23%
2.00
Change In Account Payable
-0.96
+57.68%
-2.26
-199.91%
2.26
Change In Other Working Capital
—
—
-13.63
Change In Other Current Assets
4.03
+514.79%
0.66
+113.99%
-4.69
Change In Other Current Liabilities
-2.93
-248.01%
1.98
+296.92%
-1.01
Investing Cash Flow
1.33
+160.82%
-2.18
+86.29%
-15.92
Cash Flow From Continuing Investing Activities
1.33
+160.82%
-2.18
+86.29%
-15.92
Net PPE Purchase And Sale
1.33
+160.82%
-2.18
+86.29%
-15.92
Purchase Of PPE
0.00
+100.00%
-2.18
+86.35%
-15.98
Sale Of PPE
1.33
0.00
-100.00%
0.06
Capital Expenditure
—
-2.18
+86.35%
-15.98
Financing Cash Flow
-16.16
-208.62%
14.87
-87.51%
119.11
Cash Flow From Continuing Financing Activities
-16.16
-208.62%
14.87
-87.51%
119.11
Net Issuance Payments Of Debt
-16.16
-209.78%
14.72
+54603.70%
-0.03
Issuance Of Debt
0.00
-100.00%
14.74
0.00
Repayment Of Debt
-16.16
-73331.82%
-0.02
+18.52%
-0.03
Long Term Debt Issuance
0.00
-100.00%
14.74
0.00
Long Term Debt Payments
-16.16
-73331.82%
-0.02
+18.52%
-0.03
Net Long Term Debt Issuance
-16.16
-209.78%
14.72
+54603.70%
-0.03
Net Common Stock Issuance
—
0.00
-100.00%
118.58
Proceeds From Stock Option Exercised
0.00
-100.00%
0.29
-91.02%
3.22
Net Other Financing Charges
—
-0.13
+95.04%
-2.66
Changes In Cash
-46.33
+25.46%
-62.16
-272.40%
36.06
Beginning Cash Position
73.81
-45.72%
135.97
+36.09%
99.91
End Cash Position
27.47
-62.78%
73.81
-45.72%
135.97
Free Cash Flow
-31.50
+59.10%
-77.03
+7.32%
-83.12
Interest Paid Supplemental Data
0.20
-72.74%
0.74
+8133.33%
0.01
Common Stock Issuance
—
0.00
-100.00%
118.58
Issuance Of Capital Stock
—
0.00
-100.00%
118.58
Net Preferred Stock Issuance
—
—
0.00
Preferred Stock Issuance
—
—
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category